Aplastic anemia: dramatic increase in hematologic response with eltrombopag
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Addition of eltrombopag (Promacta) to horse antithymocyte globulin (Atgam, ATG) and cyclosporine in patients with previously untreated severe aplastic anemia resulted in dramatic increases in hematologic response compared with historical outcomes.
Why this matters
There have been numerous unsuccessful efforts to improve upon outcomes in this setting.
Phase 1/2 study to investigate the efficacy and safety of adding eltrombopag to ATG and cyclosporine as first treatment in 92 patients with previously untreated severe aplastic anemia.
Patients were enrolled in 3 consecutive cohorts.
Funding: National Heart, Lung, and Blood Institute.
Best results were observed in the cohort in which eltrombopag was...